Efficacy of Single-dose First-generation 5-HT
| Autor: | Daizo, Kaito, Hirotoshi, Iihara, Norihiko, Funaguchi, Junki, Endo, Fumitaka, Ito, Komei, Yanase, Sayaka, Toyoshi, Yuka, Sasaki, Chiemi, Hirose, Natsumi, Arai, Mika, Kitahora, Yasushi, Ohno, Yoshinori, Itoh, Shinya, Minatoguchi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Aged 80 and over Male Lung Neoplasms Dose-Response Relationship Drug Vomiting Antineoplastic Agents Nausea Adenocarcinoma Middle Aged Prognosis Risk Assessment Dexamethasone Carboplatin Carcinoma Non-Small-Cell Lung Carcinoma Squamous Cell Antiemetics Humans Serotonin 5-HT3 Receptor Antagonists Drug Therapy Combination Female Receptors Serotonin 5-HT3 Aged Neoplasm Staging Retrospective Studies |
| Zdroj: | Anticancer research. 37(4) |
| ISSN: | 1791-7530 |
| Popis: | Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the weekly administration of CBDCA (area under the curve (AUC) 2 mg/ml/min) and paclitaxel (PTX: 40 mg/mThe subjects were patients with NSCLC who were administered weekly CBDCA+PTX therapy in CCRT between January 2011 and December 2016 at our Department. As an antiemetic measure, a first-generation 5-HTThe subjects we assessed in this study were 46 patients who were administered weekly CBDCA+PTX therapy in CCRT. For the overall, acute, and delayed phases, the complete response rates were 89.1%, 100%, and 89.1%, respectively. The rate of no nausea in the overall, acute, and delayed phases was 78.3%, 100%, and 78.3%, respectively. The rate of no vomiting in the overall, acute, and delayed phases was 95.7%, 100%, and 95.7%, respectively.A single dose of a first-generation 5-HT |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|